5 results on '"Spanish Group for Research on Sarcoma"'
Search Results
2. Clinical practice guidelines for the diagnosis and treatment of patients with soft tissue sarcoma by the Spanish group for research in sarcomas (GEIS)
- Author
-
Garcia del Muro, Xavier, de Alava, Enrique, Artigas, Vicenç, Bague, Silvia, Braña, Alejandro, Cubedo, Ricardo, Cruz, Josefina, Mulet-Margalef, Nuria, Narvaez, Jose A, Martinez Tirado, Oscar, Valverde, Claudia, Verges, Ramona, Viñals, Joan, Martin-Broto, Javier, Spanish Group for Research on Sarcoma, [Garcia del Muro, Xavier] Inst Catala Oncol Hosp, Barcelona, Spain, [Mulet-Margalef, Nuria] Inst Catala Oncol Hosp, Barcelona, Spain, [de Alava, Enrique] Hosp Univ Virgen del Rocio, Seville, Spain, [Martin-Broto, Javier] Hosp Univ Virgen del Rocio, Seville, Spain, [Artigas, Vicenc] Hosp Santa Creu & Sant Pau, Barcelona, Spain, [Bague, Silvia] Hosp Santa Creu & Sant Pau, Barcelona, Spain, [Brana, Alejandro] Univ Oviedo, Hosp Cent Asturias, E-33080 Oviedo, Spain, [Cubedo, Ricardo] Hosp Puerta Hierro Majadahonda, Madrid, Spain, [Cruz, Josefina] Hosp Univ Canarias, Santa Cruz De Tenerife, Spain, [Narvaez, Jose A.] Hosp Univ Bellvitge, Barcelona, Spain, [Vinals, Joan] Hosp Univ Bellvitge, Barcelona, Spain, [Martinez Tirado, Oscar] Inst Invest Biomed Bellvitge IDIBELL, Barcelona, Spain, [Valverde, Claudia] Hosp Univ Vall Hebron, Barcelona, Spain, and [Verges, Ramona] Hosp Univ Vall Hebron, Barcelona, Spain
- Subjects
Cancer Research ,medicine.medical_specialty ,Soft Tissue Neoplasm ,Core-needle-biopsy ,medicine.medical_treatment ,Antineoplastic Agents ,Soft Tissue Neoplasms ,Disease ,Isolated limb perfusion ,030230 surgery ,Toxicology ,Targeted therapy ,03 medical and health sciences ,Inflammatory myofibroblastic tumor ,0302 clinical medicine ,Biopsy ,Multidisciplinary management ,medicine ,Humans ,Pharmacology (medical) ,Doxorubicin plus ifosfamide ,Pharmacology ,Randomized phase-ii ,Soft tissue sarcoma ,medicine.diagnostic_test ,business.industry ,General surgery ,Soft tissue ,Prognostic-factors ,Sarcoma ,Evidence-based medicine ,medicine.disease ,Clear-cell sarcoma ,Surgery ,Solitary fibrous tumor ,Adjuvant chemotherapy ,Treatment ,Oncology ,Chemotherapy, Adjuvant ,Spain ,030220 oncology & carcinogenesis ,Original Article ,business ,Clinical practice guidelines ,High-dose doxorubicin - Abstract
The authors would like to thank Ron Clapp, and GEIS Clinical Research Center for their assistance in the preparation of the manuscript, Garcia Del Muro, X., De Alava, E., Artigas, V., Bague, S., Braña, A., Cubedo, R., Cruz, J., Mulet-Margalef, N., Narvaez, J.A., Martinez Tirado, O., Valverde, C., Verges, R., Viñals, J., Martin-Broto, J.
- Published
- 2015
3. Clinical practice guidelines for the diagnosis and treatment of patients with soft tissue sarcoma by the Spanish group for research in sarcomas (GEIS).
- Author
-
Garcia del Muro, Xavier, Alava, Enrique, Artigas, Vicenç, Bague, Silvia, Braña, Alejandro, Cubedo, Ricardo, Cruz, Josefina, Mulet-Margalef, Nuria, Narvaez, Jose, Martinez Tirado, Oscar, Valverde, Claudia, Verges, Ramona, Viñals, Joan, Martin-Broto, Javier, de Alava, Enrique, Artigas, Vicenç, Braña, Alejandro, Narvaez, Jose A, Viñals, Joan, and Spanish Group for Research on Sarcoma
- Subjects
TISSUE wounds ,CANCER treatment ,SARCOMA ,TUMOR diagnosis ,BIOPSY ,INTERDISCIPLINARY research ,ANTINEOPLASTIC agents ,COMBINED modality therapy ,SOFT tissue tumors ,DIAGNOSIS ,TUMOR treatment - Abstract
Soft tissue sarcomas (STS) constitute an uncommon and heterogeneous group of tumours, which require a complex and specialized multidisciplinary management. The diagnostic approach should include imaging studies and core needle biopsy performed prior to undertaking surgery. Wide excision is the mainstay of treatment for localized sarcoma, and associated preoperative or postoperative radiotherapy should be administered in high-risk patients. Adjuvant chemotherapy was associated with a modest improvement in survival in a meta-analysis and constitutes a standard option in selected patients with high-risk STS. In metastatic patients, surgery must be evaluated in selected cases. In the rest of patients, chemotherapy and, in some subtypes, targeted therapy often used in a sequential strategy constitutes the treatment of election. Despite important advances in the understanding of the pathophysiology of the disease, the advances achieved in therapeutic results may be deemed still insufficient. Moreover, due to the rarity and complexity of the disease, the results in clinical practice are not always optimal. For this reason, the Spanish Group for Research on Sarcoma (GEIS) has developed a multidisciplinary clinical practice guidelines document, with the aim of facilitating the diagnosis and treatment of these patients in Spain. In the document, each practical recommendation is accompanied by level of evidence and grade of recommendation on the basis of the available data. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
4. A Growth Modulation Index-Based GEISTRA Score as a New Prognostic Tool for Trabectedin Efficacy in Patients with Advanced Soft Tissue Sarcomas: A Spanish Group for Sarcoma Research (GEIS) Retrospective Study
- Author
-
Roberto Diaz-Beveridge, Luis Miguel De Sande-González, Antonio López Pousa, Jordi Rubió-Casadevall, Javier Martin-Broto, Pablo Luna, Juan Antonio Carrasco, Claudia M Valverde-Morales, Andres Poveda, Gloria Marquina, María Ángeles Vaz Salgado, Javier Martinez-Trufero, Antonio Gutierrez, Ana De Juan, Juana María Cano, Ibon Gurruchaga-Sotes, Isabel Sevilla, Josefina Cruz-Jurado, Jerónimo Martínez-García, Rosa Alvarez, David S. Moura, Institut Català de la Salut, [Martínez-Trufero J] Javier Martinez-Trufero, Medical Oncology Department, Hospital Universitario Miguel Servet, Zaragoza, Spain. [De Sande-González LM] Medical Oncology Department, Complejo Asistencial Universitario de Leon, Leon, Spain. [Luna P] Medical Oncology Department, Hospital Universitario Son Espases, Palma de Mallorca, Spain. [Martin-Broto J] Medical Oncology Department, Hospital Universitario Virgen del Rocio, Instituto de Biomedicina de Sevilla (IBiS, CSIC, US, HUVR), Sevilla, Spain. [Álvarez R] Medical Oncology Department, Hospital Universitario Gregorio Marañon, Madrid, Spain. [Marquina G] Medical Oncology Department, Hospital Universitario Clinico San Carlos, Madrid, Spain. [Valverde-Morales CM] Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus, [Martínez-Trufero,J, Gurruchaga-Sotes,I] Javier Martinez-Trufero, Medical Oncology Department, Hospital Universitario Miguel Servet, Zaragoza, Spain. [De Sande-González,LM] Medical Oncology Department, Complejo Asistencial Universitario de Leon, Leon, Spain. [Luna,P] Medical Oncology Department, Hospital Universitario Son Espases, Palma de Mallorca, Spain. [Martin-Broto,J] Medical Oncology Department, Hospital Universitario Virgen del Rocio, Instituto de Biomedicina de Sevilla (IBiS, CSIC, US, HUVR), Sevilla, Spain. [Álvarez,R] Medical Oncology Department, Hospital Universitario Gregorio Marañon, Madrid, Spain. [Marquina,G] Medical Oncology Department, Hospital Universitario Clinico San Carlos, Madrid, Spain. [Diaz-Beveridge,R] Medical Oncology Department, Hospital Politécnico La Fe, Valencia, Spain. [Poveda,A] Medical Oncology Department, Instituto Valenciano de Oncologia, Valencia, Spain. [Cano,JM] Medical Oncology Department, Hospital General de Ciudad Real, Ciudad Real, Spain. [Cruz-Jurado,J] Medical Oncology Department, Hospital Universitario Canarias, Santa Cruz de Tenerife, Spain. [López Pousa,A] Medical Oncology Department, Hospital Universitario Santa Creu i Sant Pau, Barcelona, Spain. [Vaz Salgado,MA] Medical Oncology Department, Hospital Universitario Ramon y Cajal, RYCIS, CIBERONC, Madrid, Spain. [Valverde-Morales,C] Medical Oncology Department, Hospital Universitario Vall D’Hebron, Barcelona, Spain. [Sevilla,I] Investigación Clínica y Traslacional en Cáncer, Instituto de Investigaciones Biomédicas de Málaga (IBIMA), Medical Oncology Department, Hospitales Universitarios Regional y Virgen de la Victoria de Málaga, Malaga, Spain. [Martínez-García,J] Medical Oncology Department, Hospital Virgen de la Arrixaca, Murcia, Spain. [Rubio-Casadevall,J] Medical Oncology Department, Instituto Catalan Oncologia, Girona, Spain. [De Juan,A] Medical Oncology Department, Hospital Marqués de Valdecilla, Santander, Spain. [Carrasco,JA] Medical Oncology Department, Hospital Alvaro Cunqueiro, Vigo, Spain. [Moura,DS] Instituto de Biomedicina de Sevilla (IBiS, CSIC, US, HUVR), Sevilla, Spain. [Gutiérrez,A] Hematology Department, Hospital Universitario Son Espases, 07010 Palma de Mallorca, Spain., and This research was funded by the Spanish Group for Research on Sarcoma (grant number: NA) and partially by PharmaMar. PharmaMar S.A. did not have any role in study design, or in collection, analysis and interpretation of data.
- Subjects
0301 basic medicine ,Oncology ,Advanced soft tissue sarcomas ,Cancer Research ,Multivariate analysis ,sarcoma ,Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Epidemiologic Study Characteristics as Topic::Epidemiologic Studies::Case-Control Studies::Retrospective Studies [Medical Subject Headings] ,Trabectedina ,España ,Diseases::Neoplasms::Neoplasms by Histologic Type::Neoplasms, Connective and Soft Tissue::Sarcoma [Medical Subject Headings] ,Other subheadings::Other subheadings::/drug therapy [Other subheadings] ,Metastasis ,Prognostic score ,Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans [Medical Subject Headings] ,0302 clinical medicine ,Trabectedin ,Tumors de parts toves ,Soft tissue sarcoma ,Pronóstico ,Soft tissue ,Liposarcoma ,lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,prognostic score ,GEISTRA, L-sarcoma, growth modulation index, prognostic score, sarcoma, trabectedin ,030220 oncology & carcinogenesis ,trabectedin ,Sarcoma ,L-sarcoma ,medicine.drug ,medicine.medical_specialty ,Chemicals and Drugs::Organic Chemicals::Sulfur Compounds::Thiazoles::Thiamine::Thiamine Triphosphate [Medical Subject Headings] ,GEISTRA ,Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Statistics as Topic::Analysis of Variance::Multivariate Analysis [Medical Subject Headings] ,Otros calificadores::Otros calificadores::/farmacoterapia [Otros calificadores] ,Neoplasms::Neoplasms by Site::Soft Tissue Neoplasms [DISEASES] ,epidemiología y bioestadística::epidemiología::usos de la epidemiología::efectividad [SALUD PÚBLICA] ,lcsh:RC254-282 ,Article ,Diseases::Neoplasms::Neoplasms by Histologic Type::Neoplasms, Connective and Soft Tissue::Sarcoma::Leiomyosarcoma [Medical Subject Headings] ,03 medical and health sciences ,Internal medicine ,medicine ,Diseases::Neoplasms::Neoplasms by Histologic Type::Neoplasms, Connective and Soft Tissue::Sarcoma::Liposarcoma [Medical Subject Headings] ,neoplasias::neoplasias por localización::neoplasias de los tejidos blandos [ENFERMEDADES] ,Geographical Locations::Geographic Locations::Europe::Spain [Medical Subject Headings] ,business.industry ,Retrospective cohort study ,medicine.disease ,030104 developmental biology ,Spain ,Medicaments - Eficàcia ,Analytical, Diagnostic and Therapeutic Techniques and Equipment::Diagnosis::Prognosis [Medical Subject Headings] ,Epidemiology and Biostatistics::Epidemiology::Uses of Epidemiology::Effectiveness [PUBLIC HEALTH] ,Leiomiosarcoma ,business ,growth modulation index - Abstract
The aim of this study was to identify an easily reliable prognostic score that selects the subset of advanced soft tissue sarcoma (ASTS) patients with a higher benefit with trabectedin in terms of time to progression and overall survival. A retrospective series of 357 patients with ASTS treated with trabectedin as second- or further-line in 19 centers across Spain was analyzed. First, it was confirmed that patients with high growth modulation index (GMI >, 1.33) were associated with the better clinical outcome. Univariate and multivariate analyses were performed to identify factors associated with a GMI >, 1.33. Thus, GEISTRA score was based on metastasis free-interval (MFI ≤ 9.7 months), Karnofsky <, 80%, Non L-sarcomas and better response in the previous systemic line. The median GMI was 0.82 (0–69), with 198 patients (55%) with a GMI <, 1, 41 (11.5%) with a GMI 1–1.33 and 118 (33.1%) with a GMI >, 1.33. The lowest GEISTRA score showed a median of time-to-progression (TTP) and overall survival (OS) of 5.7 and 19.5 months, respectively, whereas it was 1.8 and 3.1 months for TTP and OS, respectively, for the GEISTRA 4 score. This prognostic tool can contribute to better selecting candidates for trabectedin treatment in ASTS.
- Published
- 2021
5. Management of patients with rare adult solid cancers: objectives and evaluation of European reference networks (ERN) EURACAN.
- Author
-
Blay JY, Casali P, Ray-Coquard I, Seckl MJ, Gietema J, de Herder WW, Caplin M, Klümpen HJ, Glehen O, Wyrwicz L, Peeters R, Licitra L, Girard N, Piperno-Neumann S, Kapiteijn E, Idbaih A, Franceschi E, Trama A, Frezza AM, Hohenberger P, Hindi N, Martin-Broto J, Schell J, Rogasik M, Lejeune S, Oliver K, de Lorenzo F, and Weinman A
- Abstract
About 500,000 patients with rare adult solid cancers (RASC) are diagnosed yearly in Europe. Delays and unequal quality of management impact negatively their survival. Since 2017, European reference networks (ERN) aim to improve the quality of care of patients with rare disease. The steering committee of EURACAN, including physicians, researchers and patients review here the previous actions, present objectives of the ERN EURACAN dedicated to RASC. EURACAN promoted management in reference centres, and equal implementation of excellence and innovation in Europe and developed 22 clinical practice guidelines (CPGs). Additionally, fourteen information brochures translated in 24 EU languages were developed in collaboration with patient advocacy groups (ePAGs) and seventeen training session were organized. Nevertheless, connections to national networks in the 26 participating countries (106 centres), simplification of cross-border healthcare, international multidisciplinary tumour boards, registries and monitoring of the quality of care are still required. In this Health Policy, evaluation criteria of the performances of the network and of health care providers are proposed., Competing Interests: WwdH Consulting fees Novartis, Ipsen, Camurus, ITM Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events Novartis, Ipsen, Camurus, ITM (personal). AMF: Grants or contracts from any entity Advenchen Laboratories, Amgen DompÈ, AROG Pharmaceuticals, Bayer, Blueprint Medicines, Daiichi Sankyo, Deciphera, Eisai, Eli Lilly, Epizyme Inc, GlaxoSmithKline, Karyopharm Pharmaceuticals, Novartis, Pfizer, PharmaMar, SpringWorks. Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid EURACAN Coordination team G1 ISG Coordination of the WG dedicated to education (Institution). AI: Grants or contracts from any entity: Carthera Transgene NutrithÈragËne Sanofi Consulting fees: Novocure Leo Pharma Novartis Boehringer Ingelheim Polytone Laser INC. Support for attending meetings and/or travel Carthera, Enterome (To my institution, unrelated to the submitted work)/DSMB: NCT02331498 (unpaid). HJK: Participation on a Data Safety Monitoring Board or Advisory Board Janssen, Astra Zeneca, MSD (Advisory board, payments to my institution). JM-B Grants or contracts from any entity (PharmaMar Novartis Eisai IMMIX Biopharma Boehringer Ing. PTC Bio (Preclinical grant, to the institution); Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events PharmaMar Invited speaker Eli-Lilly Invited speaker Bayer Invited speaker Eisai Invited speaker Roche Invited speaker Daichii Invited speaker; IDMC: Tracon –(personal). LL: Grants or contracts: Adlai Nortye, Astrazeneca, BMS, DEbiopharm Eisai Eli Lilly, Exeliixis, Hoffman la Roche Isa therapeutics, Kura oncology, Merck Serono, MSD, MSD, Nektar, Novartis, Regeneron, Roche, Sanofi, Syneos, Sun Pharma, Incyte Bioscienc ee international, Gilead Science, Genmab, Merck KGa (to the institution); Consulting fees: MSD IT, Merck Serono, Spa Healthcare professional, Merck Healthcare Kga, GSK, Hoffman la Roche, ALX oncology, EMD Serono Research and Development Inst. , Boehringer Ingelheim Int. Payment or honoraria for lectures: Merck Serono Spa, Merck Healthcare Kga, Neutron therapeutics Inc, Merck& Co IOnc., Astrazeneca, MSD IT, EMDSerono Research & Development Institute Inc, Mirati THerapeutics inc, F Hoffmann la Roche Ltd, Novartis Pharma Spa, Janssen Research and Development LLC, SEagen International GmbH, Eisai Europe Limited, Genmab US Inc, AstraZeneca uK Ltd, Abbvie Srl (Personal). MC: Consulting fees AAA-NOVARTIS To me IPSEN Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events AAA-NOVARTIS IPSEN INCA (personal). MJS: Consulting fees:Gamida (personal). PGC: Grants or contracts: Advenchen, Amgen, Dompé, AROG Pharma, Bayer, Blueprint Medicines, Boehringer ingelheim, Diichi Sankyo, Deciphera, Eisai, Eli Lilly, Epizyme inc, Foghorn Ther. Inc, Glaxo, Hutchinson Mredipharma Ltd, Inhibrx Inc, Karyopharm pharmaceuticals, PTC ther, Novartis, Pfize, Pharmamar, Rain Oncology, Springworks (to institution). JYB Grants or contracts: EURACAN grant French NCI (INCA) NETSARC + grant, INTERSARC + grant, LYRICAN + grant; DEpGYN RHU; Fondation ARC:ACSE grant (to the institution); Ligue Nationale contre le Cancer ACSE Grant; Comité de l’Ain de la Ligue contre le Cancer Grant (all for the institution). The other authors report no conflict of interest related to this work., (© 2024 The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.